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Correlated amino acid mutation analysis has been widely used to infer functional interactions between different sites in
a protein. However, this analysis can be confounded by important phylogenetic effects broadly classifiable as background
linkage disequilibrium (BLD). We have systematically separated the covariation induced by selective interactions between
amino acids from background LD, using synonymous (S) vs. amino acid (A) mutations. Covariation between two amino acid
mutations, (A,A), can be affected by selective interactions between amino acids, whereas covariation within (A,S) pairs or (S,S)
pairs cannot. Our analysis of the pol gene — including the protease and the reverse transcriptase genes — in HIV reveals that
(A,A) covariation levels are enormously higher than for either (A,S) or (S,S), and thus cannot be attributed to phylogenetic
effects. The magnitude of these effects suggests that a large portion of (A,A) covariation in the HIV pol gene results from
selective interactions. Inspection of the most prominent (A,A) interactions in the HIV pol gene showed that they are known
sites of independently identified drug resistance mutations, and physically cluster around the drug binding site. Moreover, the
specific set of (A,A) interaction pairs was reproducible in different drug treatment studies, and vanished in untreated HIV
samples. The (S,S) covariation curves measured a low but detectable level of background LD in HIV.
Citation: Wang Q, Lee C (2007) Distinguishing Functional Amino Acid Covariation from Background Linkage Disequilibrium in HIV Protease and
Reverse Transcriptase. PLoS ONE 2(8): e814. doi:10.1371/journal.pone.0000814
INTRODUCTION
Correlated amino acid mutation analysis has been widely used to
infer functional interactions between different sites in a protein [1–
12]. Typically, a strong correlation between amino acid mutations
is interpreted as evidence of functional interactions under
substantial selection pressure. For example, statistical covariation
of amino acid mutations in HIV has revealed interesting biological
interactions between sites, and constraints imposed by protein
structure [13–19]. Therefore, studying covariation of amino acid
mutations in HIV will improve our understanding of HIV drug
resistance as well as help vaccine design [13,18]. Studies of
covariation in different regions of HIV genome have identified
a number of correlated amino acid mutation pairs, many of which
have known biological interactions [13–19].
However, such covariation analysis can be confounded by
important phylogenetic effects [13,14]. One major challenge for
covariation analysis is distinguishing covariation that is genuinely
due to selection pressure, from covariation that is simply due to co-
inheritance from a common ancestor. When a mutation first
occurs in an individual chromosome, other mutations are already
present in that chromosome, and initially this mutation will be
inherited in 100% linkage with those other mutations. Such co-
occurrence due to common ancestry is classified as background
linkage disequilibrium (BLD) [20] (Fig. 1A). Over time, however,
such linkage will be scrambled by events such as recombination
and mutation, returning to equilibrium (no statistical association
between them). For example, homologous recombination events
between any pair of mutations will gradually scramble any linkage
between the mutation pair at a rate that is proportional to the
physical distance between them, the recombination rate, and the
passage of time. This raises several questions. How to distinguish
BLD from the covariation due to selection pressure? What fraction
of covariation is BLD? How strong is BLD in HIV? The evidence
from different studies has been ambiguous. On one hand, studies
indicate that phylogenetic effects in HIV are strong. Phylogenetic
analysis has successfully inferred HIV transmission history from
HIV sequences [21,22]. On the other hand, HIV’s high mutation
rate [23,24], recombination rate [25–27], and short generation
time [28–30] should reduce the phylogenetic effect significantly.
It should also be emphasized that phylogenetic analysis can be
confounded by strong selection pressure. Whereas phylogenetic
analysis interprets the presence of the same mutation in several
individuals as evidence of common ancestry, selection pressure
creates bias for ‘‘convergent evolution’’ [31] in which the same
mutation can evolve independently many times due to positive
selection. Such hidden biases are incompatible with the assump-
tions of classical phylogenetic analysis [32]. For example, one
study has reported that selection pressure for drug resistance can
cause incorrect phylogenetic inferences from HIV sequences
(compared with the known transmission history) [33].
Thus, it is important to develop methods that can distinguish
these two causes of covariation. Recently, analytical methods such
as parametric bootstrap [34] and phylogeny-based shuffling [35]
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PLoS ONE | www.plosone.org 1 August 2007 | Issue 8 | e814have been applied to estimate what fraction of covariation arises
from phylogenetic effects. In this paper we take a different
approach, based on comparing levels of covariation between
different types of mutation pairs, such as pairs of amino acid
mutations (A,A) vs. pairs of synonymous mutations (S,S). Whereas
(A,A) pairs are subject to both phylogenetic effects and selection
pressure on functional interactions between amino acid sites, (S,S)
pairs cannot be subject to this type of selection pressure (since they
leave the amino acid sequence unchanged) (Fig. 1). We have
therefore used synonymous mutations to measure background LD
[20], to systematically distinguish covariation from phylogenetic
effects vs. other sources of covariation, independent of mathemat-
ical model assumptions. Throughout this paper we will use the
term ‘‘covariation’’ to refer to observed statistical association
(without implying any specific interpretation of its cause);
‘‘background linkage disequilibrium’’ to indicate the specific
interpretation of co-inheritance from a common ancestor; and
‘‘selective interactions’’ to indicate the specific interpretation of
selection pressure for co-occurrence of a given pair of amino acid
mutations. The ‘‘selective interactions’’ include 3D structural
interactions (both local and long-range) as well as phenotypic
covariation due to shared selection pressure. It should also be
noted that selection on nucleotides (e.g. constraints on the RNA
structure in viruses [36,37]) rather than on amino acids can also
cause BLD, as measured by (S,S) covariation, thus may contribute
to the covariation of all three types of mutation pairs, (A,A), (A,S)
and (S,S), in this study.
RESULTS
Metrics of LD in HIV and Its Comparison with
Background LD
First, we performed standard analyses of Linkage Disequilibrium
(LD) on a dataset of about 50,000 HIV-1 pol gene sequences of
subtype B, covering a 1.4 kb region of the HIV protease and
reverse transcriptase (RT) genes, mostly from patients under
antiretroviral drug treatment [38]. Following the procedure of the
Human Genome HapMap project [39], we applied a minimum
frequency criteria to the data before measuring the LD. After
applying the frequency cutoff of 2%, our dataset included 398
distinct single nucleotide mutations, each with 3260 observation
counts on average. It should be noted that due to the very large
size of this dataset and the high rate of mutation in HIV, we
detected a very high density of mutations, including mutations at
the majority of individual nucleotide sites, most with large
numbers of observations. This provided a uniquely high-resolution
mutation dataset for mapping LD. The density of mutations
(observations per nucleotide) in this dataset is 100-fold higher than
in the data from the Human Genome HapMap project [39].
We computed D9 and r [40], two measures of statistical
association commonly used to measure LD in many organisms, e.g.
human [41–44]. Both metrics displayed a pattern in HIV similar
to that in human, decaying as a function of distance (Fig. 2A, and
Fig. S1A), as expected from population genetics theory. However,
they indicated weaker LD than that in human [41–44], which is
consistent with HIV’s high mutation rate [23,24], recombination
rate [25–27], and short generation time [28–30], the factors that
reduce LD according to the population genetics theory.
Another crucial difference between HIV and classical examples
of LD analysis (i.e. the human data), is that this region of the HIV
genome experiences very strong positive selection pressure due to
antiviral drug treatments [45,46]. To control for possible LD
caused by amino acid selection pressure, we repeated this LD
analysis strictly for pairs of synonymous mutations. Such mutations
do not change the amino acid sequence and thus are not subject to
amino acid selection pressure, yielding a measurement of
‘‘background LD’’ free of amino acid selection artifacts [20]. D9
and r metrics of the background LD decayed as a function of
physical distance (Fig. 2A, and Fig. S1A). However, the average
background LD by these metrics was smaller than the average LD,
across the whole one kb region. The average D9 for background
LD decayed from 0.02 for adjacent mutations to 0.01 for distances
of 0.4 kb or more, about two-fold lower than the standard LD
curve over the same distance range (Fig. 2A). The average r
showed a similar pattern (Fig. S1A). This suggests that selection
pressure plays an important role in shaping LD in HIV.
Comparing Covariation of (A,A), (A,S) and (S,S) in HIV
To examine this hypothesis further, we subdivided mutation pairs
into three groups: pairs of synonymous mutations (S,S); pairs of
amino acid mutations (A,A); and pairs consisting of one amino
acid mutation and one synonymous mutation (A,S). (A,A) pairs
experience both phylogenetic effects and possible selective
interactions; that is, (A,A) pairs that together increase reproductive
fitness may be selected for co-occurrence. By contrast, since
Figure 1. Schema of Separating Selective Interactions from Back-
ground Linkage Disequilibrium (BLD). (A) Mutation covariation due to
BLD. Covariation of mutation A and R (shown in multiple sequence
alignment, right) is caused by co-inheritance of the two mutations from
a common ancestor (shown in the phylogenetic tree, left). (B) Mutation
covariation due to selective interactions. Relative fitness models for
mutations x and y, the double mutant (xy), and wildtype (0). Two
models are contrasted: top, independent (additive) fitness effects don’t
cause amino acid mutation covariation; bottom, selective interactions
cause covariation of x and y. (C) Distinguishing BLD vs. fitness using
pairs of amino acid mutations (A) and synonymous (S) mutations.
doi:10.1371/journal.pone.0000814.g001
Selective Interactions vs. BLD
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both (S,S) and (A,S) pairs are not subject to amino acid selective
interaction effects. Thus, the extent of selective interaction effects
can be estimated by a systematic pattern of excess covariation
specifically for (A,A) pairs relative to that for (S,S) and (A,S) pairs.
We first compared the (A,A), (A,S) and (S,S) covariation in the
same dataset of 50,000 HIV-1 samples. After applying minimum
frequency cutoff of 2%, 124 amino acid mutations and 274 silent
mutations were included, yielding 7626 (A,A) pairs, 33976 (A,S)
pairs, and 37401 (S,S) pairs. Compared with (A,S) and (S,S), (A,A)
covariation was dramatically higher, in both D9 and r (Fig. 2, and
Fig. S1). Only (A,A) pairs showed D9 greater than 0.8 and many
more (A,A) pairs showed strong covariation (D9.0.5) than (A,S)
and (S,S) pairs (Fig. 2C, 2D, 2E). Furthermore, the average
covariation of (A,A) was much higher than that of (A,S) and (S,S)
(Fig. 2B). The average D9 of (A,A) gradually declined from 0.18 to
0.03 over about 1000 bases, while the average D9 of (A,S) and
(A,A) started at less than 0.05 and rapidly dropped to 0.01 at
around 300 bases. On average, (A,A) covariation levels were two-
to five-fold higher than those of (A,S) and (S,S) across this range of
distances. The conclusion also held for the frequency cutoff of 1%
and 4% (Fig. S2 and S3). In addition, the difference in distribution
for covariation scores D9 of (A,A) vs. those of (A,S) and for (A,A) vs.
(S,S) was statistically significant (both p-values less than 10
216,
Wilcoxon rank sum test — see Materials and Methods). Thus,
a predominant fraction of (A,A) covariation does not appear to be
attributable to background LD as measured by (S,S) covariation.
It is also striking that the (A,S) and (S,S) covariation (measured
by D9 and r) behaved similarly, in contrast with (A,A) covariation.
The average D9 of (A,S) and (S,S) both started under 0.05 and
gradually decayed until they reached a flat of around 0.01 at 300
bases (Fig. 2B). The same pattern was repeated in the average r
curve (Fig. S1B). However, it is also interesting that there appear
to be slight differences between (A,S) and (S,S) at short distances
(less than 200 bases). The average D9 value for (A,S) was
significantly higher (up to 0.04) than (S,S) for adjacent mutations,
but decayed more rapidly, so that this difference vanished beyond
300 bases. This higher value of (A,S) vs. (S,S) is consistent with the
known strong positive selection for amino acid mutations in this
region [45,46], since (A,S) pairs would be directly affected by such
potential selective sweep events [47,48], whereas (S,S) pairs can
only be affected indirectly (i.e. only by selective sweep for a third
mutation that is a positively selected amino acid mutation).
Comparing Covariation of (A,A), (A,S) and (S,S) in the
Stanford-Treated Dataset
To assess the reproducibility of these results, we repeated this
analysis of (A,A), (A,S) and (S,S) covariance in a second,
Figure 2. (A,A) Covariation Is Dramatically Higher Than (A,S) and (S,S) Covariation in the Specialty Dataset. (A) Sliding window results of average
D9. All mutation pairs, black; silent mutation pairs (S,S) only, green. Each sliding window contains 4% of the data points in the set. (B) Sliding window
results of average D9. Amino acid mutation pairs (A,A), red; amino acid mutations to silent mutations (A,S), blue; silent mutation pairs (S,S), green.
Each sliding window contains 2% of the data points in the set. (C–E) Plots of D9 against the physical distance (base) within the mutation pair for C)
(A,A), D) (A,S) and E) (S,S).
doi:10.1371/journal.pone.0000814.g002
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samples of subtype B covering either protease or RT (Stanford-
Treated; see Materials and Methods). 73 amino acid mutations
and 103 silent mutations (mutation frequency $5%; see Materials
and Methods) were included in the analysis.
Although the average number of samples per site in Stanford-
Treated was less than one tenth of the Specialty dataset, we found
the same covariance pattern — the (A,A) covariation (D9) was
much stronger than that of (A,S) and (S,S) (both p-values less than
10
27, Wilcoxon rank sum test — see Materials and Methods), and
the covariation levels of (A,S) and (S,S) were similar (p-
value=0.89, Wilcoxon rank sum test — see Materials and
Methods). The average D9 of (A,A) started at around 0.20 and
declined to 0.07 over a scale of 800 bases; while for (A,S) and (S,S),
the average D9 started less than 0.07 and then both fluctuated at
around 0.05 (Fig. 3A). The average r showed a similar pattern,
differing from D9 mainly in measurement scale (Fig. S4A). Overall,
(A,A) covariation was about two- to four-fold higher than (A,S) and
(S,S) covariation levels. Again, the (A,S) and (S,S) curves were
largely indistinguishable within the range of sampling variance
inherent in the dataset (Fig. 3A). These data demonstrate again
that most (A,A) covariation in this region of HIV is not attributable
to background LD as measured by (S,S) covariation, suggesting
a dominant role for selective interactions due to selection pressure
imposed by antiviral drug treatment.
To exclude the possibility that the consistent pattern between
Specialty and Stanford-Treated datasets results from overlapping
samples, we eliminated from the Specialty dataset all sequences
with 98% or higher identity to samples in the Stanford dataset and
re-analyzed the Specialty dataset. After the filtering, the (A,A)
covariation level is still much higher than (A,S) and (S,S) across all
distances (Fig. S5).
Comparing Covariation of (A,A), (A,S) and (S,S) in the
Stanford-Untreated Dataset
To test the role of drug-induced selection via a negative control,
we carried out the same analysis in a set of samples collected from
untreated patients (Stanford-Untreated; see Materials and Meth-
ods). Previous studies have showed that comparison of these
Treated vs. Untreated datasets can identify the effects of antiviral
drug treatment [15,18]. The Untreated dataset contained about
4,500 drug-naive samples covering either protease or RT (see
Materials and Methods). 42 amino acid mutations and 107 silent
mutations (mutation frequency $5%) were included in the analysis.
Strikingly, the large difference in covariation between (A,A) and
(A,S)/(S,S) disappeared in the untreated dataset. The average D9
of (A,A) fluctuated around the average D9 of (A,S) and (S,S), at
approximately 0.07 (Fig. 3B). The same pattern was repeated in
the average r curve (Fig. S4B). These data provide a clear,
independent confirmation that drug-induced selection pressure is
indeed the explanation for the surplus covariation of (A,A) pairs
(relative to background LD measured by (S,S)) in the Specialty and
Stanford-Treated datasets, both of which included drug-treated
samples.
(A,A) Pairs Near the RT Active Site Show Strong
Covariation
The (A,A) covariation decay curve (Fig. 2B) revealed a clear
double-peak for pairs between 400–550 base distance in the
Specialty dataset. Strikingly, a similar double-peak was observed at
the same location in the Stanford-Treated (A,A) curve (Fig. 3A).
We analyzed the two datasets separately to identify the mutation
pairs responsible for these two peaks. These data revealed that the
peaks were caused by the same set of mutation pairs in both
datasets. One peak resulted from strong covariation between
a cluster of mutations RT 41L and 43E with another cluster RT
208Y and 210W; while the other peak reflected strong covariation
between a cluster RT 67N and 70R with the cluster RT 208Y,
218E and 219E/Q. Interestingly, in the three-dimensional protein
structure, all these residues lie close to the reverse transcriptase
active site (Fig. 4), less than 25 A ˚ apart. Furthermore, mutations
RT 41L, 67N, 70R, 210W and 219E/Q are known RT drug
resistance mutation [49]. Thus every single one of the (A,A)
covariation pairs observed in these peaks consisted of either one,
or two known drug-resistance mutations. This analysis of the
individual (A,A) covariation pairs provides independent confirma-
tion that these specific residues are positively selected for drug-
resistance.
Figure 3. (A,A) Covariation Is Dramatically Higher than (A,S) and (S,S) Covariation in the Stanford-Treated Dataset but not the Stanford-
Untreated Dataset. Sliding window results of average D9 in A) Stanford-Treated Dataset and B) Stanford-Untreated Dataset. Amino acid mutation
pairs (A,A), red; amino acid mutations to silent mutations (A,S), blue; silent mutation pairs (S,S), green. Each sliding window contains 4% of the data
points in the set.
doi:10.1371/journal.pone.0000814.g003
Selective Interactions vs. BLD
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Specialty Dataset
To provide a comprehensive analysis of the specific (A,A) pairs
that showed significant evidence of selective interactions, we
constructed two-dimensional maps of the statistical strength of
covariation between all possible pairs of codons positions in HIV
protease, for (A,A), (A,S) and (S,S) (Fig. 5). We used Fisher’s exact
test to calculate the covariation score h (see Materials and
Methods), which detects statistically significant covariation even in
cases with smaller counts. No minimum frequency criteria was
applied. This allows us to comprehensively compare the co-
variation of different types of mutation pairs. In this analysis, we
used the Specialty dataset, due to its much larger number of
samples (about 50,000). For each pair of codon positions, the map
displays the highest level of covariation measured for mutations at
that pair (see Materials and Methods).
These data reveal several striking differences between (A,A),
(A,S) and (S,S) covariation. First, the (A,A) map contains a large
fraction (2.6%) of strong covariation effects (h.5 at 95%
confidence; see Materials and Methods), compared with only
a small fraction for (A,S) (0.3%) and (S,S) (0.3%). Second, whereas
strong (A,A) covariation broadly distributed across the whole map
(Fig. 5A), in the (A,S) and (S,S) maps covariation clustered close to
the diagonal (Fig. 5B and 5C), i.e. for codon positions that are close
in the sequence. These data suggest that background LD decays
rapidly, within 100 nt (about 30 amino acids). The fact that (A,A)
covariation extended more broadly, indicates that it arises from
a different process than background LD. Third, a large fraction
(30 out of 53) of the codon positions identified by (A,A) covariation
are known drug-resistance mutation sites [49] in HIV protease (for
the list of drug-resistance codons identified, see Materials and
Methods), confirming again that these covariation effects involve
drug-resistance selection.
Correlation of the Covariation Between
Independent Datasets
We have shown that the level of (A,A) covariation is higher than
(A,S) and (S,S) covariation in both drug-treated datasets (Specialty;
Stanford-Treated). However, do these independent datasets
display the same covariation effects? To answer this question, we
compared the covariation measurements for each (A,A) pair from
these two datasets. For each (A,A) pair, we plotted the covariation
value observed in the Specialty dataset against the covariation
value observed in the Stanford-Treated dataset (Fig. S6).
Strikingly, the (A,A) pairs that covaried in the Specialty dataset
Figure 4. Amino Acid Mutation Pairs that Show Strong Covariation
Are Close to Active Sites in RT. HIV-1 reverse transcriptase (RT)
structure (PDB accession number 3HVTA) is shown using Protein
Explorer (www.proteinexplorer.org). The RT41, 43 and 44, red; RT 67 and
70, green; RT 208, 210, 218, 219, yellow; active sites 110,185 and 186 in
magenta. The grey sphere cluster is the nucleoside reverse transcriptase
inhibitor — Nevirapine.
doi:10.1371/journal.pone.0000814.g004
Figure 5. The Covariation Maps of Three Different Types of Mutation Pairs in HIV Protease. The covariation maps of A) amino acid mutation pairs
(A,A), B) amino acid mutations to silent mutations (A,S) and C) silent mutation pairs (S,S). The X and Y axes represent the codon positions in protease.
Each cell represents the strongest covariation value (h; see Materials and Methods) measured for any mutation pair of the designated type between
the two positions. The strength of the covariation is depicted on a color scale, with yellow indicating covariation score (h) larger than 1 and varying
shades up to blue indicating covariation score (h) larger than 5 (the covariation of two mutations is at least five times greater than random). White
indicates no evidence of covariation.
doi:10.1371/journal.pone.0000814.g005
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covariation values in the two datasets showed strong quantitative
agreement, yielding a high correlation coefficient of 0.83 (See
Materials and Methods) between these two independent datasets.
In contrast, for (A,S) and (S,S) pairs, the covariation detected in
these two datasets was low, both giving the correlation coefficients
of 0.35. This indicates that a single, consistent pattern of selective
interactions is reproducibly discovered in the two independent
datasets, but only for (A,A) covariation.
To assess whether drug treatment acts as the consistent amino
acid selection in these two datasets, we compared the (A,A)
covariation in the Treated dataset with that in the Untreated one.
We found that the high consistence of (A,A) covariation between the
Specialty and the Treated (correlation coefficient 0.83) disappeared
in the comparison between the Untreated and the Treated, leaving
a correlation coefficient of only 0.39 (Fig. S6D). This suggests that
drug treatment (shared by the Specialty and the Treated datasets,
but not the Untreated dataset) causes the nearly identical pattern of
selective interactions found in these two independent datasets.
DISCUSSION
We have systematically separated the covariation induced by
selective interactions from background LD, using silent (S) and
amino acid (A) mutations. Selective interactions between amino
acids can be detected by (A,A) pairs, but not by (A,S) or (S,S) pairs.
Our analysis of the pol gene in HIV suggests that a large portion of
(A,A) covariation in HIV results from selective interactions.
Meanwhile, the (S,S) covariation curves suggest a low but detectable
level of background LD in HIV. Although HIV has extremely high
mutation and recombination rate, as well as short generation time,
the (S,S) covariation metrics were still able to detect some BLD,
decreasing as a function of physical distance (Fig. 2).
Several lines of evidence demonstrate the robustness of these
conclusions. First, the same results were found by three different
measurements of covariation: the widely used D9 and r metrics,
and Fisher’s exact test. Second, these results were reproduced in
independent experimental studies (the Specialty and Stanford-
Treated datasets). Third, the high level of consistency between
independent (A,S) and (S,S) covariation curves suggests that the
much higher level of covariation observed for (A,A) pairs cannot
be attributed to background LD. Fourth, we also found direct
evidence that the difference in covariation levels between (A,A) vs.
(A,S)/(S,S) is due to selection, specifically, antiviral drug treatment,
by comparing treated vs. untreated datasets. Fifth, the most
prominent (A,A) interactions in the HIV pol gene have been
independently identified as drug resistance mutations that
physically cluster around the drug binding site. Finally, the specific
set of (A,A) interaction pairs was reproducible in different drug
treatment studies, and vanished in untreated HIV samples. Our
result agrees with the ‘observation of positive epistasis in HIV [50].
A previous study in plastid genomes also indicates that the
significant covariation in plastid genomes is likely due to changes
in the selective constraints of amino acids [51].
Could the surplus of the (A,A) covariation compared with that
of (A,S) and (S,S) in the treated datasets (Specialty and Stanford-
Treated) be an artifact of differences in the intrinsic mutation rates
between silent and amino acid mutations (e.g. silent mutations are
more likely to be transitions than transversions, thus evolving
faster)? We directly tested this possibility by performing the same
analysis in samples from untreated patients (Stanford-Untreated).
Such an artifact should have also have been observed in the
untreated dataset. Yet, the difference between (A,A) vs. (A,S)/(S,S)
disappeared in the untreated dataset (Fig. 3), indicating that this
difference was due specifically to drug-treatment. It should also be
noted that in addition to drug treatment, there are other sources of
selection, such as immune pressure. Like the drug-induced
selection, this too only causes (A,A) but not (A,S) or (S,S)
covariation. However, we didn’t detect a significant difference
between (A,A) vs. (A,S)/(S,S) in the untreated samples, suggesting
our approach is not sensitive enough to detect weaker selection.
How might drug treatment cause the dramatic increase in
covariation of amino acid mutation pairs observed in HIV?
Several models are possible. 1) Drug treatment selects for
mutations that directly cause drug resistance (called primary
mutations), many of which may have secondary effects such as
reducing protein stability and/or other aspects of viral fitness.
These mutations can in turn induce selection pressure for
mutations that compensate for these effects (called accessory
mutations; e.g. a mutation that restores the protein stability). Such
secondary selection effects will cause a pattern of covariation of
primary mutations with their associated accessory mutations. By
contrast, in the untreated samples, where such positive selection
forces are presumably weaker, we did not detect significant
evidence of selective interactions. 2) The covariation can be caused
by shared selection pressure among amino acid mutations. If
mutation X and Y are independently selected for under the same
drug treatment, the two mutations are likely to covary. To
distinguish the aforementioned two possibilities, we need to
estimate the fitness of mutation X and Y separately and compare
the sum with the fitness of the XY double mutation, which is
beyond the scope of this study.
Our data also indicate that accurate measurement of back-
ground LD is useful to improve the accuracy of functional
interaction prediction. Accurate measurement of the background
LD would enable calculation of a threshold value above which the
statistics will have a specific probability of resulting from causes
other than background LD. Comparison of statistical values of
covariation calculated from (A,A) pairs with the background (i.e.
(S,S) covariation) allows identification of pairs of sites having
a specific probability of interacting due to selection on amino
acids. Such phylogenetic effects should be taken into consideration
in covariation analysis of amino acid interactions.
In this paper, we have only analyzed the pol gene, which is
known to have experienced strong drug selection. The same
method should be applied in the other regions of the HIV genome.
We expect the (A,S) and (S,S) covariation, while still consistent
with each other, varies across the HIV genome due to different
phylogeny across the genome. The comparison of (A,A) co-
variation with that of (A,S)/(S,S) across the HIV genome will
provide a global view of the influence of selection on mutation
covariation. For example, such comparison in the env gene will
hopefully improve our understanding of the interplay between the
host selection and phylogeny in that region. The same analysis
could also be done in subtypes other than subtype B.
MATERIALS AND METHODS
HIV-1 sequence data
The Specialty dataset contained 48,927 subtype B sequences,
mostly from patients under antiretroviral drug treatment. Multiple
sequence alignments and mutation detection were performed as
previously described [38,52]. All these sequences covered the
whole protease and part of the RT. The Treated and the
Untreated datasets were downloaded from Stanford database
(http://hivdb.stanford.edu/) [53], selecting only subtype B
sequences. In the Treated dataset, there were 1795 protease
sequences treated with protease inhibitor (this subset were used to
calculate the covariation between mutations in protease) and 5121
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reverse transcriptase inhibitor (NRI) or non-nucleoside reverse
transcriptase inhibitor (NNRI) (this subset were used to calculate
the covariation between mutations in RT), including 1320 samples
that cover both protease and reverse transcriptase sequences (this
subset were used to calculate the covariation between mutations in
protease and those in RT). In each subset, we required a minimum
mutation frequency of 5%. In the Untreated dataset, there were
2620 PI-naı ¨ve protease sequences and 1795 NRI/NNRI-naı ¨ve
reverse transcriptase sequences, including 1208 samples that have
both protease and reverse transcriptase treatment-naı ¨ve.
Measurements of covariation for individual
mutation pairs
We used the Fisher exact test [54,55] to test for non-random
associations between mutation a at position X and mutation b at
position Y, by computing the p-value for the two-sided test using
the 262 contingency table: NXaYb,N XaY0,N X0Yb and NX0Y0?N-
XaYb is the number of samples that have mutation a at position X
and also mutation b at position Y; NXaY0 is the number of samples
that have mutation a at position X and but no kind of mutation at
position Y; NX0Yb is the number of samples that have no mutation
at position X and have mutation b at position Y; NX0Y0 is the
number of samples that have mutation at neither position. We
computed the odds ratio, its confidence interval (95%two-sided) and
p-value using the fisher.test function from the statistical software
package R. Note: the maximum likelihood estimator for h is
provided by (NXaYb?NX0Y0)/(NXaY0?NX0Yb); for independent muta-
tions Xa and Yb, h=1. We calculated D9 and r following the
standard procedures [56–58], using p1=(N XaYb+NXaY0)/N,
q1=(N XaYb+NX0Yb)/N, x11=N XaYb/N, where N=NXaYb+N-
XaY0+NX0Yb+NX0Y0.. Finally, we used Wilcoxon rank sum test
(wilcox.test function in the R package) to compare different types of
mutation pairs with respectto their covariation score (e.g. D9). The p-
value is calculated for the null hypothesis that the covariation scores
for the two types of mutation pairs are from the same distribution.
Average LD as a function of distance
Mutation pairs with negative LD were excluded. Mutation pairs
were ranked by physical distance. We calculated smoothed curves
using a sliding window, the window width of 2% or 4% of the total
data, and an offset for neighboring windows of the 1/2 the window
width.
Covariation map
For each pair of mutations, we used Fisher exact test to compute
a p-value for statistically significant covariation, along with a lower-
bound estimate for the strength of covariation h based on the 95%
confidence interval. Only statistically significant mutation pairs
(p,10
26 for a single pair, yielding a significance level of 0.01 after
the Bonferroni correction) were included in our analysis. For
a given codon position pair, the strongest covariation value h for
any pair of mutations at the two positions (of the designated type:
(A,A), (A,S), or (S,S)) was displayed in the map.
In protease, the drug-resistant codons identified by (A,A)
covariation are 10, 13, 16, 20, 24, 30, 32, 33, 35, 36, 43, 46, 47,
48, 50, 53, 54, 58, 60, 62, 63, 71, 73, 74, 82, 84, 85, 88, 90 and 93.
Comparing covariation between datasets
To test whether the covariation derived from two datasets, X and
Y, was consistent, we plotted for every mutation pair the
covariation measurement r in X vs. that in Y. We also calculated
the correlation coefficient between the two datasets. Since
correlation coefficient is very sensitive to outliers, the lowest
correlation from 2000 bootstrap replicates (the R boot library) was
taken as the correlation score between X and Y.
SUPPORTING INFORMATION
Figure S1 (A,A) Covariation Measured by r Is Dramatically
Higher than (A,S) and (S,S) Covariation in the Specialty Dataset.
(A) Sliding window results of average r. All mutation pairs, black;
silent mutation pairs (S,S) only, green. Each sliding window
contains 4% of the data points in the set. (B) Sliding window results
of average r. Amino acid mutation pairs (A,A), red; amino acid
mutations to silent mutations (A,S), blue; silent mutation pairs
(S,S), green. Each sliding window contains 2% of the data points in
the set. (C–E) Plots of r against the physical distance (base) within
the mutation pair for C) (A,A), D) (A,S) and E) (S,S).
Found at: doi:10.1371/journal.pone.0000814.s001 (0.84 MB TIF)
Figure S2 (A,A) Covariation Is Still Dramatically Higher than
(A,S) and (S,S) Covariation in the Specialty Dataset Using 0.01 As
the Mutation Frequency Cutoff. (A–C) Plots of D’ against the
physical distance (base) within the mutation pair for A) amino acid
mutation pairs (A,A), B) amino acid mutations to silent mutations
(A,S) and C) silent mutation pairs (S,S). (D, E) Sliding window
results of average D) D’ and E) r. (A,A), red; (A,S), blue; (S,S), green.
Each sliding window contains 2% of the data points in the set.
Found at: doi:10.1371/journal.pone.0000814.s002 (0.88 MB TIF)
Figure S3 (A,A) Covariation Is Still Dramatically Higher than
(A,S) and (S,S) Covariation in the Specialty Dataset Using 0.04 As
the Mutation Frequency Cutoff. (A–C) Plots of D’ against the
physical distance (base) within the mutation pair for A) amino acid
mutation pairs (A,A), B) amino acid mutations to silent mutations
(A,S) and C) silent mutation pairs (S,S). (D, E) Sliding window
results of average D) D’ and E) r. (A,A), red; (A,S), blue; (S,S), green.
Each sliding window contains 2% of the data points in the set.
Found at: doi:10.1371/journal.pone.0000814.s003 (0.55 MB TIF)
Figure S4 (A,A) Covariation Measured by r Is Dramatically
Higher than (A,S) and (S,S) Covariation in the Stanford-Treated
Dataset But Not the Stanford-Untreated Dataset. Sliding window
results of average r in (A) Stanford-Treated Dataset and (B)
Stanford-Untreated Dataset. Amino acid mutation pairs (A,A),
red; amino acid mutations to silent mutations (A,S), blue; silent
mutation pairs (S,S), green. Each sliding window contains 4% of
the data points in the set.
Found at: doi:10.1371/journal.pone.0000814.s004 (0.17 MB TIF)
Figure S5 (A,A) Covariation Is Still Dramatically Higher than
(A,S) and (S,S) Covariation in the Specialty Dataset After
Excluding Samples That Have Nucleotide Sequence Similarity
98% Or Greater With Any Sample In the Stanford-Treated
Dataset. (A–C) Plots of D’ against the physical distance (base)
within the mutation pair for A) amino acid mutation pairs (A,A), B)
amino acid mutations to silent mutations (A,S) and C) silent
mutation pairs (S,S). (D, E) Sliding window results of average D)
D’ and E) r. (A,A), red; (A,S), blue; (S,S), green. Each sliding
window contains 2% of the data points in the set.
Found at: doi:10.1371/journal.pone.0000814.s005 (0.88 MB TIF)
Figure S6 Shared Drug Treatment Leads to High Consistency
of Amino Acid Covariation between Independent Datasets. (A–C)
The covariation measurement r in the Specialty dataset plotted
against that in the Stanford-Treated dataset for A) amino acid
mutation pairs (A,A), B) amino acid mutations to silent mutations
(A,S) and C) silent mutation pairs (S,S). (D–F) The covariation
Selective Interactions vs. BLD
PLoS ONE | www.plosone.org 7 August 2007 | Issue 8 | e814measurement r in the Stanford-Untreated dataset plotted against
that in the Treated dataset, for D) (A,A), E) (A,S) and F) (S,S).
Found at: doi:10.1371/journal.pone.0000814.s006 (0.65 MB TIF)
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